Plexus Corp (PLXS) FinancialsPLXSPlexus Corp

Plexus Corp (PLXS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Healthcare/Life Sciences, accounting for 43.6% of total sales, equivalent to $466.03M. Other significant revenue streams include Industrial and Aerospace/Defense. Understanding this composition is critical for investors evaluating how PLXS navigates market cycles within the Electronic Equipment & Parts industry.

Evaluating the bottom line, Plexus Corp maintains a gross margin of 10.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.70%, while the net margin is 3.30%. These profitability ratios, combined with a Return on Equity (ROE) of 12.58%, provide a clear picture of how effectively PLXS converts its operational activities into shareholder value.

In the context of the broader market, PLXS competes directly with industry leaders such as MDA and VSH. With a market capitalization of $7.13B, it holds a leading position in the sector. When comparing efficiency, PLXS's gross margin of 10.07% stands against MDA's 19.09% and VSH's 23.34%. Such benchmarking helps identify whether Plexus Corp is trading at a premium or discount relative to its financial performance.

Plexus has demonstrated strong financial performance, with consistent revenue growth, achieving $1.31 billion in Q3 2026, a 29.7% increase year-over-year, and a gross margin of 10.07%.